Himension Capital Singapore PTE. LTD. Has $1.31 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Himension Capital Singapore PTE. LTD. grew its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 201.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 31,598 shares of the company's stock after buying an additional 21,102 shares during the period. Himension Capital Singapore PTE. LTD.'s holdings in Moderna were worth $1,314,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in MRNA. abrdn plc grew its stake in Moderna by 28.1% in the fourth quarter. abrdn plc now owns 315,912 shares of the company's stock valued at $12,842,000 after acquiring an additional 69,360 shares during the period. Y Intercept Hong Kong Ltd lifted its holdings in shares of Moderna by 30.9% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company's stock valued at $6,760,000 after purchasing an additional 23,881 shares in the last quarter. Spire Wealth Management grew its position in shares of Moderna by 2,150.4% in the 4th quarter. Spire Wealth Management now owns 23,224 shares of the company's stock valued at $966,000 after purchasing an additional 22,192 shares during the period. Geode Capital Management LLC increased its stake in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock worth $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Finally, Proficio Capital Partners LLC raised its holdings in Moderna by 4,418.9% during the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock worth $6,127,000 after buying an additional 144,099 shares during the period. Institutional investors own 75.33% of the company's stock.

Remove Ads

Moderna Stock Up 4.7 %

Shares of NASDAQ MRNA traded up $1.16 during midday trading on Friday, hitting $25.66. 5,925,956 shares of the company's stock were exchanged, compared to its average volume of 7,146,401. The firm has a market capitalization of $9.92 billion, a PE ratio of -2.77 and a beta of 2.23. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47. The company's 50 day moving average price is $31.72 and its 200 day moving average price is $41.27.

Analysts Set New Price Targets

Several research firms have recently weighed in on MRNA. Leerink Partners reduced their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. Bank of America lowered their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and cut their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Morgan Stanley decreased their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a report on Wednesday. Finally, Barclays cut Moderna from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.